Back to Search
Start Over
Inhibitors of the PD-1 Pathway in Tumor Therapy
- Source :
- The Journal of Immunology. 200:375-383
- Publication Year :
- 2018
- Publisher :
- The American Association of Immunologists, 2018.
-
Abstract
- The programmed death 1 (PD-1) pathway delivers inhibitory signals that function as a brake for immune responses. This pathway limits the initiation and duration of immune responses, thereby protecting tissues from immune-mediated damage and autoimmune diseases. However, the PD-1 pathway also inhibits immune responses to tumors. The critical role of PD-1 in preventing antitumor immunity is demonstrated by the transformative effects of PD-1 pathway blockade in a broad range of cancers with the hallmark of durability of response. Despite this success, most patients do not respond to PD-1 monotherapy, and some patients experience adverse events. In this review, we discuss the functions of the PD-1 pathway and its translation to cancer immunotherapy. We also consider current challenges and opportunities for PD-1 cancer immunotherapy, including mechanisms of response and resistance, identification of biomarkers of response to PD-1 therapy, characterization and treatment of PD-1 therapy–related adverse events, and development of safe and effective combination therapies.
- Subjects :
- 0301 basic medicine
T-Lymphocytes
medicine.medical_treatment
Programmed Cell Death 1 Receptor
Immunology
Drug Evaluation, Preclinical
Drug resistance
Article
B7-H1 Antigen
Immunomodulation
Translational Research, Biomedical
03 medical and health sciences
Antineoplastic Agents, Immunological
0302 clinical medicine
Immune system
Cancer immunotherapy
Neoplasms
Biomarkers, Tumor
Animals
Humans
Immunology and Allergy
Combined Modality Therapy
Medicine
Neoplasm
Molecular Targeted Therapy
Adverse effect
business.industry
Clinical Studies as Topic
Translation (biology)
Prognosis
medicine.disease
Blockade
Treatment Outcome
030104 developmental biology
Drug Resistance, Neoplasm
030220 oncology & carcinogenesis
Cancer research
business
Signal Transduction
Subjects
Details
- ISSN :
- 15506606 and 00221767
- Volume :
- 200
- Database :
- OpenAIRE
- Journal :
- The Journal of Immunology
- Accession number :
- edsair.doi.dedup.....548b2d76e8549ec2c6016271662b009d